INS and type 1 diabetes mellitus: In Type 1 Diabetes (TD1M), insulin analogues, both short-acting and long-acting, should always be offered as an option, which more closely reproduce the physiological needs and translate into a lower risk of hypoglycemia given the specific pharmacokinetics and pharmacodynamics of both preparations [4,5,6,7,8].